Enrich SURVEILLANCE

Advancing SARS-CoV-2 surveillance

The COVID-19 pandemic has strongly highlighted the importance of viral surveillance. Sequencing is now broadly used to monitor the viral genome and its evolution in the population, as well as to detect new emerging variants and study their impact on antiviral drugs and vaccine efficacy. High-performing sample prep workflows are needed to unlock the information from every sample. After sequencing, a reliable analytics solution is needed to accurately analyze the data. Roche is partnering with Hyrax Biosciences to provide a software solution that turns raw sequence data into meaningful results.

Enrich, sequence, and report with confidence

High-quality results	Achieve uniform and broad genome coverage with the KAPA RNA HyperCap workflow—Confidently detect and report variants with the Exatype platform
Minimize time	Save valuable time and maintain data quality by 1-hour hybridization with the KAPA HyperCap SARS-CoV-2 panel—Report your findings faster by on-cloud parallel processing using the intuitive interface of the Exatype platform
Scalability	Scale up with ease using the streamlined, automation friendly, KAPA HyperCap workflow and Hyrax Biosciences' secure, cloud-based IT infrastructure
Proven technology	Hybrid capture based methods may better detect relatively divergent SARS-CoV-2 sequences of new emerging variants[1]
Proven expertise	Roche and Hyrax Biosciences combine their proven expertise in sample prep and reporting to offer a complete, end-to-end solution for SARS-CoV-2 surveillance

From sample preparation to meaningful results



Viral RNA in host RNA background → Library Prep with KAPA RNA HyperPrep Kit → Target Enrichment with KAPA HyperCap SARS-CoV-2 panel → Final library enriched with viral targets → Next Gen Sequencing → Analysis and reporting using the Exatype platform

[1]Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. 8 Jan 2021 | COVID-19: Laboratory and diagnosis. World Health Organization.

Rely on proven expertise in viral genome sequence analysis

Hyrax Biosciences is driven by one overriding goal: to automate the analysis and interpretation of pathogen DNA-sequence data. Exatype—their DNA analysis platform—delivers consistently accurate and clear reporting at scale, without the need for human intervention. The read mapping and alignment algorithms are the foundation of Exatype and are designed to enable analysis of any disease through customizable applications in the near future.

Enjoy a user-friendly experience

- Detect emerging variants with confidence with the KAPA HyperCap SARS-CoV-2 panel and the Exatype platform
- Experience an intuitive interface with five simple steps to data analysis at **hpr.exatype.com**
- Review and download variant reports, coverage plots, sequencing metrics, consensus sequences for GISAID upload





Start today at hpr.exatype.com

Learn more at www.hyraxbio.com/roche sequencing.roche.com

Published by:

Roche Sequencing Solutions, Inc.
4300 Hacienda Drive
Pleasanton, CA 94588

sequencing.roche.com

MC--07573 08/21